RxDoctor Payments Data

Scott Mitchell, MD

Internal Medicine · Carthage, NYNPI 1811936081

Payments from drug & device makers

$432in general payments, 2019–2025

Across 26 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$211
  • Johnson & Johnson$74
  • Merck$50
  • Dentsply Sirona Inc$38
  • AbbVie$29
  • Abbott$19
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk14$211
Johnson & Johnson4$74
Merck3$50
Dentsply Sirona Inc1$38
AbbVie(2 entities)2$29
Abbott1$19
AstraZeneca1$12

How this compares

$432 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$230,064
Medicare patients
649
Services billed
3,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate100$123,040
TrulicityDulaglutide86$116,941
JardianceEmpagliflozin68$101,732
EliquisApixaban82$99,322
OzempicSemaglutide41$54,737
XareltoRivaroxaban34$41,388
FarxigaDapagliflozin Propanediol28$35,245
Breo ElliptaFluticasone/Vilanterol57$33,618
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,653
MounjaroTirzepatide17$26,228
InvokanaCanagliflozin13$23,918
TradjentaLinagliptin26$18,445
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog47$18,007
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$15,102
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$50$123,040100 claims
Johnson & JohnsonXarelto, Invokana$74$65,30647 claims
Novo NordiskOzempic$211$54,73741 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$12$54,05166 claims
AbbVieSynthroid$29$2,73455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Carthage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →